At the EB World Congress in London, UK, InMed’s scientific team officially revealed CBN as the active pharmaceutical ingredient (API) in INM-755 while exhibiting preclinical data in support of the INM-755 program in epidermolysis bullosa (EB).
InMed’s scientific posters from EB World Congress can be viewed here.
Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,
A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s
#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8
© Copyright 2025 InMed Pharmaceuticals Inc.
"*" indicates required fields